Form 4: Marinus Pharmaceuticals Director Christine Silverstein Reports Stock and Option Awards

Director Christine Silverstein reported the acquisition of restricted stock units and stock options in Marinus Pharmaceuticals, according to a Form 4 filing.

Summary

• Christine Silverstein, a director of Marinus Pharmaceuticals, reported changes in beneficial ownership on June 18, 2024.
• She acquired 2,300 shares of common stock through restricted stock units (RSUs) at a price of $0.
• These RSUs vest fully on July 15, 2025, contingent upon her continued service with Marinus Pharmaceuticals.
• Each RSU represents the right to receive one share of common stock of the Issuer.
• Silverstein also acquired options to purchase 10,450 shares of common stock at an exercise price of $1.40.
• These options vest fully on July 15, 2025, also contingent upon her continued service.
• Following these transactions, Silverstein directly owns 14,100 shares of common stock and options for 10,450 shares.
• The filing was signed by Debra A. Mohollen, Attorney-in-Fact, on June 20, 2024.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard compensation practices and aligns director interests with shareholders. There are no red flags or negative indicators.

Positives

• The grant of RSUs and stock options to a director aligns her interests with those of the shareholders.
• The vesting schedule tied to continued service incentivizes the director to remain with the company.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of RSUs and options is contingent on continued service, suggesting an expectation of ongoing involvement.

Industry Context

Form 4 filings are standard disclosures for corporate insiders and provide transparency regarding their transactions in the company's securities. This filing indicates continued investment and alignment of interests by a key member of the board.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of compensation for directors in publicly traded companies, particularly in the pharmaceutical industry.
• Vesting schedules of one year are common, but can vary depending on the company's compensation policies and the director's role.
• Comparing the size of the grant to those of directors at similar-sized pharmaceutical companies (e.g., Sage Therapeutics, Neurocrine Biosciences) would provide further context.

Stakeholder Impact

• The grant of equity to a director can be viewed positively by shareholders as it aligns management's interests with theirs.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Form 4, beneficial ownership, stock options, restricted stock units, MRNS, Marinus Pharmaceuticals, Silverstein, director